Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE: INF108F in Infants With FPIAP
NCT05793112Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in food protein-induced allergic proctocolitis (FPIAP) comparing INF108F with Placebo (2 arms). Primary endpoint: Changes to Gut Microbiome Composition at Day 28. Started Sep 2023; status: completed.
02
Drugs
INF108F
03
Conditions
food protein-induced allergic proctocolitis (FPIAP)
Beyond the preview
Go deeper on NCT05793112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05793112.